Teacher Retirement System of Texas Decreases Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Teacher Retirement System of Texas lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 9.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,680 shares of the specialty pharmaceutical company’s stock after selling 888 shares during the quarter. Teacher Retirement System of Texas’ holdings in Collegium Pharmaceutical were worth $259,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Collegium Pharmaceutical by 1.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after purchasing an additional 339 shares during the period. Foundry Partners LLC grew its holdings in Collegium Pharmaceutical by 2.4% in the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock worth $463,000 after acquiring an additional 381 shares during the last quarter. SummerHaven Investment Management LLC grew its holdings in Collegium Pharmaceutical by 1.9% in the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $727,000 after acquiring an additional 448 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Collegium Pharmaceutical by 4.5% in the 1st quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company’s stock worth $326,000 after acquiring an additional 477 shares during the last quarter. Finally, Virtus Fund Advisers LLC grew its holdings in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 565 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Finally, Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 5th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.75.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $31.20 on Friday. The company has a debt-to-equity ratio of 3.30, a quick ratio of 1.01 and a current ratio of 1.08. The firm has a fifty day moving average price of $30.14 and a 200 day moving average price of $29.71. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of 25.57 and a beta of 0.64.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The business had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same quarter last year, the business earned $1.45 EPS. Collegium Pharmaceutical’s revenue for the quarter was up 22.7% compared to the same quarter last year. As a group, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical announced that its board has approved a share repurchase program on Monday, July 7th that authorizes the company to repurchase $150.00 million in shares. This repurchase authorization authorizes the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, Director John Gordon Freund sold 6,601 shares of the firm’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $30.62, for a total value of $202,122.62. Following the transaction, the director owned 70,658 shares of the company’s stock, valued at $2,163,547.96. This trade represents a 8.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.51% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.